Medication Guide

In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.

Axitinib(Inlyta)

Used for treating advanced renal cell carcinoma following failure of a prior systemic therapy.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：124
Belzutifan(Welireg)

Applicable to von Hippel-Lindau (VHL) disease patients requiring treatment for renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastoma, or pancreatic neuroendocri···【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：103
Capivasertib(Truqap)

Capivasertib is suitable for the treatment of adult patients with specific types of breast cancer.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：97
Sunitinib(Sutent)

Sunitinib is a Broad-spectrum antitumor agents.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：70
Palbociclib(Ibrance)

Applicable for the treatment of adult patients with advanced or metastatic breast cancer who are hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-···【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：115
Ribociclib(Kisqali)

Ribociclib is a Broad-spectrum antitumor agents.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：93
Anagrelide(Agrylin)

Thrombocythemia【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：87
Binimetinib(Mektovi)

Binimetinib can be used for the treatment of melanoma and non-small cell lung cancer.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：87
Elacestrant(Orserdu)

Elacestrant is suitable for the treatment of specific types of breast cancer.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：107
Resmetirom(Rezdiffra)

Non-cirrhosis non-alcoholic steatohepatitis【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：73
Futibatinib(Lytgobi)

Carcinoma of bile duct【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：118
Tazemetostat(Tazverik)

Tazemetostat is a Broad-spectrum antitumor agents.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：71

home page previous 43 43/98 next last page

News

The U.S. FDA approved the combination of Pembrolizumab and Enfortumab vedotin-ejfv for the treatment
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】

Recommended：4502025-17-12
Lucius Pharmaceuticals Laos launched lorlatinib, a third-generation targeted drug for lung cancer
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】

Recommended：6372024-09-07
Imfinzi received approval in the U.S., becoming the first and only immuno-combination therapy for BC
On May 28, 2026, AstraZeneca announced that its immunotherapy drug Imfinzi (durvalumab) in combinati···【more】

Recommended：942026-01-06
FDA approves niraparib in combination with abiraterone acetate plus prednisone for metastatic castra
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】

Recommended：4162025-15-12
FDA Approves First Cellular Therapy to Treat Patients with Severe Aplastic Anemia
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】

Recommended：4382025-10-12
FDA Approves Lisocabtagene Maraleucel for the Treatment of Relapsed or Refractory Marginal Zone Lymp
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】

Recommended：4242025-08-12
The FDA has approved pirtobrutinib for the treatment of chronic lymphocytic leukemia (CLL) and small
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】

Recommended：4772025-04-12
Combination therapy of tucatinib and T-DM1 significantly improves progression-free survival in patie
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】

Recommended：3862025-01-12

Lucius Pharmaceuticals

Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More

Hospital Departments

Medication Guide

Related Articles

Axitinib(Inlyta)

Belzutifan(Welireg)

Capivasertib(Truqap)

Sunitinib(Sutent)

Palbociclib(Ibrance)

Ribociclib(Kisqali)

Anagrelide(Agrylin)

Binimetinib(Mektovi)

Elacestrant(Orserdu)

Resmetirom(Rezdiffra)

Futibatinib(Lytgobi)

Tazemetostat(Tazverik)

News

The U.S. FDA approved the combination of Pembrolizumab and Enfortumab vedotin-ejfv for the treatment

Lucius Pharmaceuticals Laos launched lorlatinib, a third-generation targeted drug for lung cancer

Imfinzi received approval in the U.S., becoming the first and only immuno-combination therapy for BC

FDA approves niraparib in combination with abiraterone acetate plus prednisone for metastatic castra

FDA Approves First Cellular Therapy to Treat Patients with Severe Aplastic Anemia

FDA Approves Lisocabtagene Maraleucel for the Treatment of Relapsed or Refractory Marginal Zone Lymp

The FDA has approved pirtobrutinib for the treatment of chronic lymphocytic leukemia (CLL) and small

Combination therapy of tucatinib and T-DM1 significantly improves progression-free survival in patie

Sotorasib

Adagrasib

Larotrectinib

Lorlatinib

Gilteritinib

Capmatinib

Selinexor

Ivosidenib

Mobocertinib

Olaparib

Product

Product

Contact US